Touch-friendly controls, biometric login, and in-app support contribute to a seamless session
There are few data on treatment efficacy, aside from occasional case reports [93] and case series [94] of adult patients treated with IBATs
How to drug our way out of the obesity crisis (or not): the roll-out of semaglutide
Highlights from Novo Nordisks presentation include (see Figure 1): Analysis of the three components in MACE: Semaglutide 2.4 mg reduced the risk of Non-fatal myocardial infarction by 28% Cardiovascular death by 15% (not statistically significant over the length of the trial) Non-fatal stroke by 7% (not statistically significant over the length of the trial) Analysis of confirmatory secondary endpoints: Semaglutide 2.4 mg reduced the risk of Composite heart failure events, comprising cardiovascular death, urgent heart failure visits and hospitalisations, by 18% Death from any cause by 19% Note: Since the result on cardiovascular death, the first confirmatory secondary endpoint, was not statistically significant over the length of the trial, the remaining secondary confirmatory endpoints were not tested for superiority due to hierarchical testing
The medication's multi-target approach suggests it may possess a tolerable safety profile similar to current weight loss prescriptions once fully approved
